For the third consecutive year, Concerto is responsible for producing the annual report for ThromboGenics. Specializing in ophthalmic research, the company is on track to marketing a new molecule, Ocriplasmine. It is therefore slowly leaving the world of research to adopt a more commercial approach. This development is quite logically reflected in the report.
